"Argentina Pharmaceuticals & Healthcare Report Q3 2012" Now Available at Fast Market Research
BMI View: The attractiveness of Argentina's pharmaceutical market to drug companies is deteriorating due to the country's unsustainable macroeconomic trajectory and the resurgence of nationalism. The double-digit growth rates forecast over the five years through to 2016 are mainly driven by inflationary pressure, even though demand continues to grow. The intellectual property (IP) regime's shortcomings and especially the government's support for state-operated domestic drugmakers remain a threat to multinational pharmaceutical companies.
View full press release